Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms Capacity 2
  • Sponsors Genentech; InterMune

    • Most Recent Events

    • 30 Jun 2023 Results of pooled analysis (from studies ASCEND (NCT01366209), CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), RECAP (NCT00662038), PASSPORT (NCT02699879), and SP-IPF (NCT02951429)published in the Advances in Therapy
    • 19 Oct 2022 Results(n=345) of Post Hoc Analysis of two studies( CAPACITY NCT00287729; NCT00287716) assessing Clinical Characteristics and Outcomes in Patients with Idiopathic Pulmonary Fibrosis (Ipf) by Pulmonary Vascular Phenotype presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians
    • 19 May 2021 Results of pooled analysis CAPACITY studies (NCT00287729 and NCT00287716), and from all patients in GIPF-001 (NCT00047645) and RIFF (Cohort A) (NCT01872689) assessing change in the DLco measurements over 6-month intervals, presented at the 117th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top